Acknowledgements
Cancer, P., Leukemia, Lymphoma
CANCER, EVANS, LEUKEMIA, LYMPHOMA
This study was supported by Eisai Pharmaceuticals, the Leukemia & Lymphoma Society, and the Rising Tide Foundation for Clinical Cancer Research. O.A.-W. is supported in part by the Edward P. Evans Foundation, NIH/NCI (R01 CA251138 and R01 CA242020), NIH/NHLBI (R01 HL128239), the Rising Tide Foundation for Clinical Cancer Research, and the Leukemia & Lymphoma Society. OA-W and ES are supported by NIH/NCI P50 CA254838-01.